Dynamic ploidy changes drive fluconazole resistance in human cryptococcal meningitis

119Citations
Citations of this article
142Readers
Mendeley users who have this article in their library.

Abstract

BACKGROUND. Cryptococcal meningitis (CM) causes an estimated 180,000 deaths annually, predominantly in sub-Saharan Africa, where most patients receive fluconazole (FLC) monotherapy. While relapse after FLC monotherapy with resistant strains is frequently observed, the mechanisms and impact of emergence of FLC resistance in human CM are poorly understood. Heteroresistance (HetR) — a resistant subpopulation within a susceptible strain — is a recently described phenomenon in Cryptococcus neoformans (Cn) and Cryptococcus gattii (Cg), the significance of which has not previously been studied in humans. METHODS. A cohort of 20 patients with HIV-associated CM in Tanzania was prospectively observed during therapy with either FLC monotherapy or in combination with flucytosine (5FC). Total and resistant subpopulations of Cryptococcus spp. were quantified directly from patient cerebrospinal fluid (CSF). Stored isolates underwent whole genome sequencing and phenotypic characterization. RESULTS. Heteroresistance was detectable in Cryptococcus spp. in the CSF of all patients at baseline (i.e., prior to initiation of therapy). During FLC monotherapy, the proportion of resistant colonies in the CSF increased during the first 2 weeks of treatment. In contrast, no resistant subpopulation was detectable in CSF by day 14 in those receiving a combination of FLC and 5FC. Genomic analysis revealed high rates of aneuploidy in heteroresistant colonies as well as in relapse isolates, with chromosome 1 (Chr1) disomy predominating. This is apparently due to the presence on Chr1 of ERG11, which is the FLC drug target, and AFR1, which encodes a drug efflux pump. In vitro efflux levels positively correlated with the level of heteroresistance. CONCLUSION. Our findings demonstrate for what we believe is the first time the presence and emergence of aneuploidy-driven FLC heteroresistance in human CM, association of efflux levels with heteroresistance, and the successful suppression of heteroresistance with 5FC/FLC combination therapy.

References Powered by Scopus

Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of America

2128Citations
N/AReaders
Get full text

Global burden of disease of HIV-associated cryptococcal meningitis: an updated analysis

1439Citations
N/AReaders
Get full text

The genome of the basidiomycetous yeast and human pathogen Cryptococcus neoformans

589Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Tackling the emerging threat of antifungal resistance to human health

548Citations
N/AReaders
Get full text

Drug resistance and tolerance in fungi

373Citations
N/AReaders
Get full text

The impact of the fungus-host-microbiota interplay upon Candida albicans infections: Current knowledge and new perspectives

215Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Stone, N. R. H., Rhodes, J., Fisher, M. C., Mfinanga, S., Kivuyo, S., Rugemalila, J., … Bicanic, T. (2019). Dynamic ploidy changes drive fluconazole resistance in human cryptococcal meningitis. Journal of Clinical Investigation, 129(3), 999–1014. https://doi.org/10.1172/JCI124516

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 52

67%

Researcher 17

22%

Lecturer / Post doc 5

6%

Professor / Associate Prof. 4

5%

Readers' Discipline

Tooltip

Biochemistry, Genetics and Molecular Bi... 24

31%

Immunology and Microbiology 19

24%

Medicine and Dentistry 18

23%

Agricultural and Biological Sciences 17

22%

Article Metrics

Tooltip
Social Media
Shares, Likes & Comments: 4

Save time finding and organizing research with Mendeley

Sign up for free